Management of Hypertension in NIDDM Patients on Dialysis

Introduction to Hypertension Management

The American Society of Nephrology recommends that for patients with non-insulin-dependent diabetes mellitus (NIDDM) receiving dialysis, beta-blockers and calcium channel blockers are the safest and most effective first-line antihypertensive agents, with ACE inhibitors/ARBs as reasonable second-line options, while prioritizing volume management before initiating pharmacotherapy 1, 2, 3

Before starting or escalating antihypertensive medications, address volume overload through dialysis optimization and sodium restriction, as volume excess underlies most hypertension in dialysis patients 1, 2
If blood pressure remains elevated after achieving euvolemia, then pharmacologic therapy is indicated 1

Beta-blockers demonstrate the strongest mortality benefit in dialysis patients with diabetes, according to the American Heart Association 4, 5
Carvedilol reduced death and cardiovascular death versus placebo in hemodialysis patients with dilated cardiomyopathy, as reported by the European Society of Cardiology 4, 5
Atenolol showed fewer heart failure hospitalizations compared to ACE inhibitors in hypertensive hemodialysis patients with left ventricular hypertrophy, as noted by the American College of Cardiology 4, 5
Critical consideration for dialyzability: Nondialyzable beta-blockers (propranolol) may provide better intradialytic arrhythmia protection than dialyzable agents (atenolol, metoprolol), though carvedilol carries higher intradialytic hypotension risk, according to the National Kidney Foundation 1, 2
For patients with frequent intradialytic hypotension, avoid nondialyzable agents, as recommended by the European Renal Association 1, 2
Amlodipine reduced cardiovascular events versus placebo in hypertensive hemodialysis patients in randomized controlled trials, as reported by the American Society of Hypertension 4, 5, 3
Amlodipine is associated with decreased total and cardiovascular mortality in observational studies, according to the International Society of Hypertension 3
Amlodipine is preferred when patients lack specific cardiovascular indications for beta-blockers, as recommended by the American College of Cardiology 3

ACE inhibitors/ARBs may reduce left ventricular mass index according to meta-analyses, as reported by the European Society of Cardiology 4, 5, 3
ACE inhibitors/ARBs may preserve residual kidney function, particularly important in peritoneal dialysis patients, according to the National Kidney Foundation 4, 5, 3
Fosinopril did not reduce cardiovascular events or death compared to placebo in hemodialysis patients with left ventricular hypertrophy, showing inconsistent cardiovascular outcome benefits, as noted by the American Heart Association 4, 5
Spironolactone versus placebo in dialysis patients shows mixed results for cardiovascular benefits, according to the International Society of Nephrology 4, 5

Optimize volume status first through adequate ultrafiltration and sodium restriction (target predialysis BP 140/90 mmHg), as recommended by the American Society of Nephrology 3
If coronary artery disease or heart failure present: Start with beta-blockers (preferably nondialyzable if no intradialytic hypotension), according to the American College of Cardiology 3
If no specific cardiovascular indications: Start with calcium channel blockers (amlodipine preferred), as recommended by the European Society of Cardiology 3
If blood pressure remains uncontrolled: Add ACE inhibitor/ARB as second agent, particularly if residual kidney function exists, according to the National Kidney Foundation 3
For stable intradialytic BP: Use once-daily, longer-acting medications to improve adherence and reduce pill burden, as recommended by the American Society of Nephrology 1, 2
For frequent intradialytic hypotension: Avoid nondialyzable medications and consider timing adjustments (preferentially administer at night to control nocturnal BP and minimize intradialytic hypotension), according to the European Renal Association 1, 2

Never initiate or escalate antihypertensives without first assessing volume status, as most dialysis hypertension is volume-mediated, as recommended by the American Society of Nephrology 1, 2, 3
Avoid highly dialyzable beta-blockers (atenolol, metoprolol) if intradialytic arrhythmia protection is needed, according to the National Kidney Foundation 1, 2
Avoid nondialyzable agents (carvedilol) in patients with frequent intradialytic hypotension due to increased hypotension risk, as noted by the European Renal Association 1, 2
Do not overlook residual kidney function preservation when selecting agents—ACE inhibitors/ARBs offer this benefit, according to the International Society of Nephrology 4, 5, 3
Check for postural hypotension regularly when treating with any BP-lowering drugs, as recommended by the American Heart Association 6